Open AccessUsing Mechanistic Models to Simulate Comparative Effectiveness Trials of Therapy and to Estimate Long-term Outcomes in HIV Care
Author(s) -
Mark S. Roberts,
Kimberly A. Nucifora,
R. Scott Braithwaite
Publication year - 2010
Publication title -
medical care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.632
H-Index - 178
eISSN - 1537-1948
pISSN - 0025-7079
DOI - 10.1097/mlr.0b013e3181e2b744
Subject(s) - lopinavir , efavirenz , medicine , clinical trial , hiv drug resistance , drug resistance , confidence interval , life expectancy , intensive care medicine , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , immunology , population , biology , environmental health , microbiology and biotechnology
In HIV care, it is difficult to decide when to initiate therapy, which drugs to use for initial treatment, and which drugs to use if drug resistance develops. With hundreds of possible drug regimens available and variable patterns of drug resistance, randomized controlled trials cannot answer all HIV treatment decisions. Mechanistic models of HIV infection can be used to conduct virtual therapeutic trials with the goal of predicting outcomes, some of which are long-term and may not fall within the time frame of a typical therapeutic trial.